Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. 2006

Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Increased monocyte recruitment into subendothelial space in atherosclerotic lesions is one of the hallmarks of diabetic angiopathy. The aim of this study was to determine the state of peripheral blood monocytes in diabetes associated with atherosclerosis. Diabetic patients treated with/without an oral hypoglycemic agent and/or insulin for at least 1 year were recruited (n=106). We also included 24 non-diabetic control subjects. We measured serum levels of monocyte chemoattractant protein (MCP)-1, fasting plasma glucose (FPG), HbA1c, total cholesterol, triglyceride, body mass index (BMI), high sensitivity CRP (hs-CRP) and evaluated CCR2, CD36, CD68 expression on the surface of monocytes. Serum MCP-1 levels were significantly (p<0.05) higher in diabetic patients than in normal subjects. In diabetic patients, serum MCP-1 levels correlated significantly with FPG, HbA1c, triglyceride, BMI, and hs-CRP. The expression levels of CCR2, CD36, and CD68 on monocytes were significantly increased in diabetic patients and were more upregulated by MCP-1 stimulation. Our data suggest that elevated serum MCP-1 levels and increased monocyte CCR2, CD36, CD68 expression correlate with poor blood glucose control and potentially contribute to increased recruitment of monocytes to the vessel wall in diabetes mellitus.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D054390 Receptors, CCR2 CCR receptors with specificity for CHEMOKINE CCL2 and several other CCL2-related chemokines. They are expressed at high levels in T-LYMPHOCYTES; B-LYMPHOCYTES; MACROPHAGES; BASOPHILS; and NK CELLS. Antigens, CD192,CC Chemokine Receptor 2,CCR2 Receptors,CD192 Antigens,CC CKR2B,CC Chemokine Receptor-2,CC Chemokine Receptors 2,CCR-2A MCP-1 Receptor,CCR2 Receptor,CCR2a Receptor,CCR2b Receptor,CCR2b Receptors,MCP-1 Receptor,MCP-1 Receptor 2B,MCP-1 Receptor CCR-2A,MCP-1 Receptors,MCP-1RA,MCP-1RB,Monocyte Chemoattractant Protein 1 Receptor,CCR 2A MCP 1 Receptor,Chemokine Receptor-2, CC,MCP 1 Receptor,MCP 1 Receptor 2B,MCP 1 Receptor CCR 2A,MCP 1 Receptors,MCP-1 Receptor, CCR-2A,Receptor CCR-2A, MCP-1,Receptor, CCR-2A MCP-1,Receptor, CCR2,Receptor, CCR2a,Receptor, CCR2b,Receptor, MCP-1,Receptor-2, CC Chemokine,Receptors, CCR2b,Receptors, MCP-1
D018932 Chemokine CCL2 A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS. Monocyte Chemoattractant Protein-1,Monocyte Chemotactic Protein-1,CCL2 Chemokine,Chemokine (C-C Motif) Ligand 2,Chemokines CCL2,Monocyte Chemotactic and Activating Factor,CCL2, Chemokine,CCL2, Chemokines,Chemoattractant Protein-1, Monocyte,Chemokine, CCL2,Chemotactic Protein-1, Monocyte,Monocyte Chemoattractant Protein 1,Monocyte Chemotactic Protein 1
D019707 Receptors, Chemokine Cell surface glycoproteins that bind to chemokines and thus mediate the migration of pro-inflammatory molecules. The receptors are members of the seven-transmembrane G protein-coupled receptor family. Like the CHEMOKINES themselves, the receptors can be divided into at least three structural branches: CR, CCR, and CXCR, according to variations in a shared cysteine motif. Chemokine Receptor,Chemokine Receptors,Receptor, Chemokine

Related Publications

Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
June 1999, Journal of lipid research,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
May 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
February 2009, Diabetes research and clinical practice,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
January 2002, Biochemical and biophysical research communications,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
September 2001, Arthritis and rheumatism,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
November 2020, European journal of obstetrics, gynecology, and reproductive biology,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
January 2004, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
March 2008, Clinical oral investigations,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
July 2015, Scandinavian journal of clinical and laboratory investigation,
Shinichiro Mine, and Yosuke Okada, and Takahisa Tanikawa, and Chie Kawahara, and Takahiro Tabata, and Yoshiya Tanaka
November 1999, British journal of cancer,
Copied contents to your clipboard!